Download this article

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator,
SDI-118, in development for the treatment of cognitive impairment.

Belgium – 8th May 2019 – Syndesi Therapeutics SA, a biotechnology company
developing novel modulators of the synaptic vesicle protein SV2A for the treatment of
cognitive impairment, today announced that its lead molecule, SDI-118, has entered into
Phase I clinical development.
The first-in-human Phase I study is investigating the safety, tolerability and
pharmacokinetics of single ascending doses of SDI-118 in healthy subjects. The study
also includes PET imaging in a group of subjects to directly measure the binding of SDI-
118 to SV2A in the brain and to assess the relationship between SV2A occupancy and
plasma exposure.
Jonathan Savidge, CEO of Syndesi, said “We are delighted to announce the entry of SDI-
118 into clinical development following successful completion of pre-clinical studies
during the first year following Syndesi’s incorporation. Conducting PET imaging in
parallel with the dose escalation provides us with highly valuable data very early in the
development program. This ability to measure the degree of target engagement of our
compound in humans greatly facilitates the choice of doses in future trials, de-risking
one of the major challenges in CNS drug development.”

About Syndesi Therapeutics

Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small
molecule SV2A modulators licensed from UCB. In February 2018 the company
announced €17M in Series A funding from a syndicate of Belgium and international
investors. In March 2019, Syndesi announced the award of up to €3.2 M in non-dilutive
funding from the Walloon Region to support the development of the lead molecule SDI-
118 through Phase I clinical development. Syndesi is investigating the potential of these
novel SV2A modulators to improve cognition in diseases such as Alzheimer’s Disease and
other dementias, as well other conditions such as cognitive impairment associated with
schizophrenia. For more information please visit www.syndesitherapeutics.com